{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-TRED248T/96881598-5c56-4dd0-a05d-b9a56068b0bc/PDF","dcterms:extent":"349 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-TRED248T/20a674df-d26f-4f46-8cf9-29d85d34e940/TEXT","dcterms:extent":"27 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-TRED248T","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2025","dc:creator":["Eberl, Andreja","Kadiš, Lea","Kerec Kos, Mojca"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:76"},{"@xml:lang":"sl","#text":"str. 3-9"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:230892803","URN:URN:NBN:SI:doc-TRED248T"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"incidenca"},{"@xml:lang":"sl","#text":"infuzijska reakcija"},{"@xml:lang":"sl","#text":"neželeni učinki"},{"@xml:lang":"sl","#text":"parenteralna kemoterapija"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Infuzijske reakcije po parenteralni aplikaciji citostatikov na Onkološkem inštitutu Ljubljana med leti 2019-2023| Infusion reactions following parenteral administration of cytostatic drugs at the Institute of Oncology Ljubljana between 2019 and 2023|"},"dc:description":[{"@xml:lang":"sl","#text":"Several anticancer therapies administered by the parenteral route carry a risk for infusion reactions, which are common cause of treatment interruption for patients with cancer. The study included all patients who experienced an infusion reaction during parenteral administration of chemotherapy during this period. In patients who received 14 different cytostatic drugs, infusion reactions occurred in 403 cases. The highest incidence of infusion reactions (7.42%) was observed with pegylated liposomal doxorubicin, and the lowest with cyclophosphamide (0.06%). Infusion reactions occurred most frequently during the first or second cycle of therapy with anthracyclines and taxanes and in later cycles with platinum compounds. For most therapeutic agents, except for platinum compounds, patients were able to continue chemotherapy on the same day after the onset of an infusion reaction, with recurrence being rare"},{"@xml:lang":"sl","#text":"Nekatera protitumorna zdravila, ki jih apliciramo parenteralno, predstavljajo tveganje za pojav infuzijskih reakcij, ki so pogost vzrok prekinitev zdravljenja pri bolnikih z rakom. Izvedli smo retrospektivno analizo infuzijskih reakcij na Onkološkem inštitutu Ljubljana med leti 2019 in 2023. V raziskavo smo vključili vse bolnike, ki so v navedenem časovnem obdobju med parenteralno aplikacijo citostatikov doživeli infuzijsko reakcijo. Med bolniki, ki so prejeli 14 različnih citostatičnih učinkovin, je bila infuzijska reakcija poročana v 403 primerih. Najvišjo incidenco infuzijskih reakcij (7,42 %) smo zabeležili pri pegilirani liposomalni obliki doksorubicina, najnižjo pa pri ciklofosfamidu (0,06 %). Infuzijske reakcije so bile pri antraciklinih in taksanih najpogostejše v prvem oziroma drugem ciklu terapije, pri platinovih spojinah pa v poznejših ciklih. Pri večini zdravilnih učinkovin, razen pri platinovih spojinah, so bolniki po pojavu infuzijske reakcije še isti dan nadaljevali s kemoterapijo, pri čemer so se infuzijske reakcije redko ponovile"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-TRED248T","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-TRED248T"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-TRED248T/96881598-5c56-4dd0-a05d-b9a56068b0bc/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-TRED248T/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-TRED248T"}}}}